La Lancet magazine positively evaluates the vaccine AstraZeneca of the University of Oxford. Therefore it is a safe vaccine. Vaccines are important for our health, but also for the restart of Italy. Thanks to what has been written, the magazine demonstrates the effectiveness in preventing Covid-19. Above all there is a lack of severe cases of the disease. As we read from the results. Data to date show that the vaccine is 76% effective after the first dose. Above all it resists until the second. Finally, the effectiveness increases to 82% with an interval of three months or more. These results are truly comforting.
The analysis of the Lancet magazine
The data on the Lancet magazine show how the vaccine produced by the pharmaceutical company AstraZeneca is effective in fighting the Pandemic. For example, among the qualities of the vaccine is the potential to reduce asymptomatic transmission of the virus. An important finding, especially because we are well aware of the danger of asymptomatics. The increase in infections is often due to asymptomatic subjects. Therefore, thanks to the analysis of the volunteers' weekly swabs in the British trial, a fact emerges. This is the fact that the positivity decreases by 67% after one dose. Finally, AstraZeneca points out, this demonstrates a substantial impact on the transmission of the Sars-Cov-2 virus. The population improves their state of health, the contagiousness and risks associated with our social life decrease. But the results that are published in the Lancet concern a population of 17.177 participants.
We speak of a representative statistical population. Of these we count 332 symptomatic cases of Covid. These are cases enrolled in phase 3 trials in Brazil, South Africa and in UK. Finally, there are 201 other cases compared to those previously reported. All this serves to collect as much information as possible about the statistical sample. After all, we are collecting important data. The aim is to be able to define the effectiveness of the vaccine. Obviously, our ability to improve the vaccine increases over time.
AstraZeneca safe vaccine
According to Mene Pangalos, executive vice president of R&D BioPharmaceuticals, we can comment positively on the AstraZeneca vaccine. Likewise, Pangalos reiterates that the vaccine prevents hospitalization. It also protects infected people from the risk of more severe forms. Another advantage is that the vaccine must be repeated after a long time. There is talk of long waiting times for those who have taken the first dose. So there is the possibility of vaccinating more people. The AstraZrneca vaccine uses a more specific approach, we are talking about a viral vector vaccine. It means that AstraZeneca uses a modified version of the chimpanzee's adenovirus, which is no longer able to replicate. This version becomes a vector to provide our body with instructions to synthesize the SARS-CoV-2 spike protein.
The sintering of the protein is produced by the body and serves to stimulate a specific immune response. Unfortunately, the European Medicines Agency (EMA) issues a conditional trade authorization. It is about limiting the age of the vaccine. Therefore, AstraZeneca is suitable for people under 55. According to the commission, there are tests done only on age groups younger than 60 years. This means that the vaccine for the elderly can only be authorized in the future. That is, you must first do tests to be sure of its effectiveness. It is true that at the moment the vaccination starts for the youngest with AstraZeneca. While for the elderly it continues with Pfizer / BioNtech and Moderna. It remains a positive evaluation and a success for the research. Work continues in the medical field to get out of the pandemic as soon as possible.
They talk about 60% effectiveness…too little..
Pingback: Covid, continue to strictly observe the anti-contagion rules | italiani.it